Another example of how multitargeting can be of value in AD therapy is the development of a novel “first-in-class” small molecule called CM-414 that ties HDAC inhibition with PDE5 inhibition, both of which individually have shown auspicious results (Cuadrado-Tejedor et al., 2017). Here, HDAC9 is linked to Alzheimer disease.